Expertise in
63
conditions

Dr. Carl R. Gray

Oncology
Ogden, UT 
Accepting New Patients
31 Years of Experience
Expertise in
63
conditions
Ogden, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carl Gray is an Oncologist in Ogden, Utah. Dr. Gray has been practicing medicine for over 31 years is highly rated in 63 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Paget Disease of the Breast, and Lung Cancer. Dr. Gray is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas Health Science Center, 1995
Residency
University of California Davis Medical Center
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
American Board Of Internal Medicine
Fellowships
University of California Davis Medical Center
Hospital Affiliations
Layton Hospital
McKay Dee Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Utah Hematology Oncology - 400 E
Ogden, UT 84405
Other Locations
Utah Hematology Oncology - Layton
2132 North Robins Drive, Suite 301, Layton, UT 84041
Ogden Clinic - Bountiful
Bountiful, UT 84010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Biological, Drug
Study Drugs: Dostarlimab, Niraparib
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 5 Less Clinical Trials

1 Total Publications

Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Journal: International journal of surgical oncology
Published: May 28, 2011
Similar Doctors
Expertise in
17
conditions
Dr. Ignacio Garrido-Laguna
Oncology | Hematology
Expertise in
17
conditions
Dr. Ignacio Garrido-Laguna
Oncology | Hematology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (27.3 miles away)
801-581-8793
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ignacio Garrido-Laguna is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Garrido-Laguna is highly rated in 17 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido-Laguna is currently accepting new patients.

Expertise in
24
conditions
Dr. Martha J. Glenn
Oncology | Hematology
Expertise in
24
conditions
Dr. Martha J. Glenn
Oncology | Hematology
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (27.3 miles away)
801-213-3800
Languages Spoken:
English
See accepted insurances

Martha Glenn is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Glenn is highly rated in 24 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
16
conditions
Dr. Wallace L. Akerley
Oncology | Hematology | Infectious Disease
Expertise in
16
conditions
Dr. Wallace L. Akerley
Oncology | Hematology | Infectious Disease

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (27.3 miles away)
801-581-8793
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wallace Akerley is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Akerley is highly rated in 16 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Akerley is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gray's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile